Paper Details

  1. Home
  2. Paper Details

Enzalutamide in metastatic prostate cancer before chemotherapy.

Author: , ArmstrongAndrew J, BeerTomasz M, BhattacharyaSuman, CarlesJoan, ChowdhurySimon, DavisIan D, EvansChristopher P, FizaziKarim, HiganoCelestia S, IversenPeter, JoshuaAnthony M, KimChoung-Soo, KimuraGo, LoriotYohann, MainwaringPaul, MansbachHarry, MillerKurt, NoonbergSarah B, PeraboFrank, PhungDe, RathkopfDana E, SaadFred, ScherHoward I, SternbergCora N, TaplinMary-Ellen, TombalBertrand, VennerPeter M, de BonoJohann S

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Enzalutamide is an oral medication that blocks testosterone receptors and has been shown to prolong life in men with advanced prostate cancer that has spread and no longer responds to chemotherapy. New treatments are needed for men with prostate cancer that has spread who haven't received chemotherapy and have not responded well to hormone therapy.
Paper Details　
Original Abstract of the Article :
Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the dis...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/24881730

データ提供：米国国立医学図書館（NLM）
in preparation
Date :
  1. Date Completed 2014-08-12
  2. Date Revised 2022-12-08
Further Info :

Pubmed ID

24881730

DOI: Digital Object Identifier

NIHMS677761

Related Literature

Article Analysis
・Effective treatment of prostate cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.